Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ib, randomized, placebo controlled, double blind study to determine the safety, viral suppression, pharmacokinetics and immune modulatory effects of treatment with aprepitant (Emend) in HIV infected individuals

Next Previous
X
Search
Trial Profile

A phase Ib, randomized, placebo controlled, double blind study to determine the safety, viral suppression, pharmacokinetics and immune modulatory effects of treatment with aprepitant (Emend) in HIV infected individuals

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 11 Jun 2021 Results of pooled analysis of data from 3 phase Ib studies (NCT00428519, NCT01300988, and NCT02154360) assessing the effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naive adults living with HIV published in the Medicine
    • 18 Jul 2010 Results have been presented at the 18th International AIDS Conference.
    • 27 Apr 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top